Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Oct;9(5):1724-1727.
doi: 10.21037/tlcr-20-545.

Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: are we actually ready?

Fabrizio Tabbò  1 , Maria Lucia Reale  1 , Silvia Novello  1
Affiliations
Editorial

Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: are we actually ready?

Fabrizio Tabbò et al. Transl Lung Cancer Res. 2020 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tlcr-20-545). SN has the following COI: Speaker Bureau/Advisor: Abbvie, AZ, Eli Lilly, Amgen, Roche, BMS, Takeda, Novartis, MSD, BI. SN serves as an unpaid editorial board member of Translational Lung Cancer Research from Jul 2019 to Jul 2021. The other authors have no conflicts of interest to declare.

Comment on

  • Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition).
    Liang W, Cai K, Chen C, Chen H, Fang W, Fu J, Fu X, Gao S, Hu J, Huang Y, Jiang G, Jiao W, Li S, Li G, Li H, Li H, Li X, Liang N, Liu D, Liu H, Liu J, Liu L, Liu Y, Luo Q, Ma H, Mao W, Peng Z, Qiao G, Shao G, Tan L, Tan Q, Wang Q, Wang C, Wu Q, Xu S, Xu S, Xu L, Yang Y, Yu F, Zhang B, Zhang L, Zhao B, Zhi X, Brunelli A, Petersen RH, Liu CC, Ricciuti B, Metro G, Tuzi A, Suter MB, Evison M, Seki N, Sasada S, Izumo T, Cho WC, He J; written on behalf of National Clinical Research Center for Respiratory Disease; Thoracic Surgery Branch of China International Exchange and Promotion Association for Medical and Healthcare; Chinese Alliance Against Lung Cancer; AME Thoracic Surgery Collaborative Group. Liang W, et al. Transl Lung Cancer Res. 2019 Dec;8(6):1163-1173. doi: 10.21037/tlcr.2019.12.14. Transl Lung Cancer Res. 2019. PMID: 32010594 Free PMC article. Review. No abstract available.

References

    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. 10.3322/caac.21492 - DOI - PubMed
    1. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med 2020;382:503-13. 10.1056/NEJMoa1911793 - DOI - PubMed
    1. Liang W, Cai K, Chen C, et al. Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition). Transl Lung Cancer Res 2019;8:1163-73. 10.21037/tlcr.2019.12.14 - DOI - PMC - PubMed
    1. Pirker R, Buder A, Filipits M. Osimertinib in advanced EGFR T790M-positive non-small-cell lung cancer: the clinical impact of AURA3. Transl Cancer Res 2017;6:S265-9. 10.21037/tcr.2017.03.12 - DOI
    1. Ettinger DS, Wood DE, Aisner DL et al. NCCN clinical practice guidelines in oncology: non–small cell lung cancer version 3.2020. February 11, 2020. Available online: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (22 March 2020, date last accessed).